Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
about
Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase I/II study of bi-weekly ...... based first-line chemotherapy.
@en
Phase I/II study of bi-weekly ...... based first-line chemotherapy.
@nl
type
label
Phase I/II study of bi-weekly ...... based first-line chemotherapy.
@en
Phase I/II study of bi-weekly ...... based first-line chemotherapy.
@nl
prefLabel
Phase I/II study of bi-weekly ...... based first-line chemotherapy.
@en
Phase I/II study of bi-weekly ...... based first-line chemotherapy.
@nl
P2093
P2860
P1476
Phase I/II study of bi-weekly ...... based first-line chemotherapy.
@en
P2093
Chu Matsuda
Hirofumi Yamamoto
Ho Min Kim
Junichi Nishimura
Kohei Murata
Masataka Ikeda
Mutsumi Fukunaga
Taishi Hata
Takeshi Kato
Toshihiro Kudo
P2860
P2888
P356
10.1007/S00280-017-3336-3
P577
2017-05-16T00:00:00Z